Evidence is accumulating that ursodeoxycholic acid (UDCA), an agent widely employed for gallstone dissolution, exerts therapeutic effects in chronic liver disease. UDCA is thought to act mainly by reducing the detergent properties of bile, making it less toxic for the liver cells. Confirming the results of preliminary observations double-blind, placebo-controlled trials have shown that UDCA significantly decreased serum concentrations of liver enzymes such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and γ-glutamyl transferase in primary biliary cirrhosis and other cholestatic conditions, as well as in chronic active hepatitis. A substantial improvement in liver histology has also been detected in UDCA-treated patients with primary biliary cirrhosis. The effect of UDCA in chronic hepatitis is currently a matter of investigation.
DusheikoGM: Review article: the management of hepatitis A, B, D and non-A, non-B. Aliment Pharmacol Ther1989; 3: 1–20.
2.
BenhamouJP: Traitement de la cirrhose biliaire primitive. Gastroenterol Clin Biol1987; 11: 565–567.
3.
MorisseyKPMcSherryCKSwarnRL: Toxicity of chenodeoxycholicacid in the nonhuman primate. Surgery1975; 77: 851–855.
4.
FisherDCCooperNSRoothschildMA: Effect of dietary chenodeoxycholic acid and lithocholic acid in the rabbit. Am J Dig Dis1974; 19: 877–882.
5.
WebsterKHLancasterMCHofmannAF: Influence of primary bile acid feeding on cholesterol metabolism and hepatic function in the Rhesus monkey. Mayo Clin Proc1975; 50: 134–141.
6.
FisherRLAndersonDWBoyerJL: A perspective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: the National Cooperative Gallstone Study. Hepatology1982; 2: 187–193.
7.
PhillipsMJFisherRLAndersonDW: Ultrastructural evidence of intrahepatic cholestasis before and after chenodeoxycholic acid therapy in patients with cholelithiasis: the National Cooperative Gallstone Study. Hepatology1983; 3: 209–215.
8.
HoffmanHF: Medical treatment of cholesterol gallstones by bile desaturating agents. Hepatology1984; 4 (suppl): 199–208.
9.
SchoenfieldLJLachinJM: Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann Intern Med1981; 95: 257–282.
10.
PalmerRH: Bile acids, liver injury and liver disease. Arch Intern Med1972; 130: 606–617.
11.
ArmstrongMJCareyMCThe hydrophobic – hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res1982; 23: 70–80.
12.
AttiliAFAngelicoMCantaforaA: Bile acid-induced liver toxicity: relation to the hydrophobic – hydrophilic balance of bile salts. Med Hypotheses1986; 19: 57–68.
13.
ScholmerichJBecherMSSchmidtK: Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties — studies on isolated hepatocytes and lipid membrane vesicles. Hepatology1984; 4: 661–666.
14.
KurtzWGuldutunaSLeuschnerU: Elevated liver tissue bile acids in steatosis and chronic hepatitis. In: Proceedings of the X International Meeting on Trends in Bile Acid Research. Freiburg, 9 – 11 June 1988; p. 192.
15.
AkashiYMiyazakiHYanagisawaJ: Bile acid metabolism in cirrhotic liver tissue: altered syntheses and impaired hepatic secretion. Clin Chim Acta1987; 2: 199–206.
16.
MiyazakiKNakayamaFKogaF: Effects of chenodeoxycholic and ursodeoxycholic acids on isolated adult human hepatocytes. Dig Dis Sci1984; 29: 1123–1130.
17.
KogaY: Anti-cholestatic and cytoprotective properties of ursodeoxycholic acid. Studies in vivo and in vitro. Acta Hepatol Jpn1987; 28: 1597–1604.
18.
GaettiESalvioliGFGualdiGL: Effect of bile salts on red blood cell membrane: a method to evaluate their membrane-damaging effect. In: Abstracts of the International Meeting of Pathochemistry, Pathophysiology and Pathomechanics of the Biliary System. New Strategies for the Treatment of Biliary Tract Disease. Bologna, 14 – 16 March 1988; p. 13.
19.
LeuschnerUFisherHKurtzW: Ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind trial. Gastroenterology1989; 97: 1268–1274.
20.
SheferSZakiFGSalenG: Early morphologic and enzymatic changes in livers of rats treated with chenodeoxycholic and ursodeoxycholic acids. Hepatology1983; 3: 201–208.
21.
MiyaiKToyotaNJonesHM: Protective effects of ursodeoxycholic acid against cholestatic and hepatotoxic effects of lithocholic acid. Hepatology1982; 2: 705.
22.
MiyajimaKMizoguchiYSakagamiY: Cholagogous effect of ursodeoxycholic acid in cholestatic factor-induced intrahepatic cholestasis. Acta Hepatol Jpn1986; 27: 1578–1583.
23.
KrolTKitamuraTMiyaiK: Tauroursodeoxycholate reduces ductular proliferation and portal inflammation in bile duct-ligated hamsters. Hepatology1983; 3: 880–881.
24.
CohenBIHofmannAFMosbachEH: Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit. Gastroenterology1986; 91: 189–197.
25.
SarvaRPFrommHFarvierS: Comparison of the effects between ursodeoxycholic and chenodeoxycholic acids on liver function and structure and on bile composition in the Rhesus monkey. Gastroenterology1990; 79: 629–636.
26.
ChretienYPouponRGherardtMF: Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut1989; 30: 1110–1115.
27.
BattaAKAroraRSalenG: Effects of ursodiol on biliary acid composition and conjugation in patients with primary biliary cirrhosis. Gastroenterology1990; 98: A567.
28.
CrosignaniAPoddaMCamisascaM: Biliary secretion of unconjugated bile acids in patients with primary biliary cirrhosis before and following ursodeoxycholic acid administration. Gastroenterology1990; 98: A578.
29.
GuldutunaSWunderlichNNickelA: Influence of ursodeoxycholic acid on bile acid metabolism of patients with primary biliary cirrhosis. Gastroenterology1990; 98: A590.
30.
HofmannAFPopperH: Ursodeoxycholic acid for primary biliary cirrhosis. Lancet1987; ii: 398.
31.
KitaniKOhtaMKanaiS: Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts. Am J Physiol1985; 248: G407–G417.
32.
BodeJCZelderONeubergerHO: Effect of taurocholate, dehydrocholate and secretin on biliary output of alkaline phosphatase and GOT. Helv Med Acta1973; 37: 143–151.
33.
HatoffDEHardisonGM: Bile acid-dependent secretion of alkaline phosphatase in rat bile. Hepatology1982; 3: 433–439.
34.
CrippinJSLindorKDKlugeDL: Ursodeoxycholic acid inhibits lymphocyte blastogenesis in a cholestatic model. Gastroenterology1990; 98: A578.
35.
DavidRKurtzWStrohmWD: Die Wirkung von Ursodesoxycholsaure bei chronischen Leber-erkrankugnen: eine Pilotstudie. Z Gastroenterol1985; 23: 420.
36.
FisherMMParadineME: Influence of ursodeoxycholic acid on biochemical parameters in cholestatic liver disease. Gastroenterology1986; 90: 1725.
37.
PouponRChretienYPouponRE: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?Lancet1987; i: 834–836.
38.
RaedschRStiehlATheilmannL: Influence of ursodeoxycholic acid on primary biliary cirrhosis depending on stage of the disease. Gastroenterology1989; 96: A647.
39.
OsugaTTanakaNMatsuzakiY: Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Dig Dis Sci1989; 34 (suppl 12): 49S–51S.
40.
MatsuzakiYTanakaNOsugaT: Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary cirrhosis. Am J Gastroenterol1990; 85: 15–23.
41.
KneppelhoutJCMulderCJJVan BergeGP: Effect of ursodeoxycholic acid on liver function and pruritus in PBC. Gastroenterology1990; 98: A598.
42.
PoddaMBattezzatiPMBertoliniE: Effects of ursodeoxycholic acid (UDCA) on liver function tests and bile acid metabolism in anicteric primary biliary cirrhosis. A dose – response study. Hepatology1988; 8: 1266.
43.
BattezzatiPMBertoliniECamisascaM: Effects of different doses of ursodeoxycholic acid (UDCA) on liver function indices in patients with icteric primary biliary cirrhosis (PBC). Gastroenterology1989; 96: A575.
44.
HadziyannisSJHadziyannisESMakrisA: A randomized controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC). In: Abstracts of the 40th Annual Meeting of the American Association for the Study of Liver Diseases. Chicago, 1989; p. 45.
45.
EskreisDAbroonJKatzS: Ursodeoxycholic acid treatment of primary biliary cirrhosis. Am J Gastroenterol1988; 83: 1065.
46.
O'BrienCBSeniorJRSternliebJM: Ursodiol treatment of primary biliary cirrhosis. Gastroenterology1990; 98: A617.
47.
PoddaMBattezzatiPMCrosignaniA: Ursodeoxycholic acid (UDCA) for symptomatic primary biliary cirrhosis (PBC): a double-blind multicenter trial. In: Abstracts of the 40th Annual Meeting of the American Associationfor the Study of Liver Diseases. Chicago, 1989; p. 284.
48.
SpiveyJRCaldwellSHReddyKR: Combined used of colchicine and ursodeoxycholic acid in the therapy of primary biliary cirrhosis. Gastroenterology1990; 98: A635.
49.
RodaEMazzellaGBazzoliF: Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis. Dig Dis Sci1989; 34 (suppl 12): 525–585.
50.
StiehlARaedschRTheilmannL: The effect of ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis. Gastroenterology1989; 96: A664.
51.
BattaAKAroraRSalenG: Effect of ursodiol (UDCA) on bile acid metabolism in primary sclerosing cholangitis (PSC). Gastroenterology1989; 96: A575.
52.
ChazouileeresOPouponRCapronJP: Is ursodeoxycholic acid an effective treatment for primary sclerosing cholangitis?Gastroenterology1989; 96: A583.
53.
O'BrienCSeniorJRBattaAK: Ursodeoxycholic acid treatment produces marked clinical and biochemical amelioration of primary sclerosing cholangitis. Gastroenterology1989; 96: A640.
54.
SeniorJRO'BrienCBWiesnerRH: Ursodiol therapy of primary sclerosing cholangitis reduces the predicted mortality risk. Gastroenterology1990; 98: A360.
55.
UllrichDRatingDSchroterW: Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. Lancet1987; ii: 1324.
56.
NittonoHTokitaAHayashiM: Ursodeoxycholic acid in biliary atresia. Lancet1988; i: 528.
57.
ColomboC: The effect of ursodeoxycholic acid therapy in liver disease associated with cystic fibrosis. In: Abstracts of the 2nd International Meeting on Pathochemistry, Pathophysiology and Pathomechanics of the Biliary System. Bologna, 1921 March 1990; p. 138.
58.
LeviJDeFeliceRRamakrishnanR: Short-term effects of ursodeoxycholic acid in chronic cholestatic disorders of childhood. Gastroenterology1990; 98: A603.
59.
CrosignaniAPoddaMBertoliniE: Failure of ursodeoxycholic acid to prevent the occurrence of cholestasis in benign recurrent intrahepatic cholestasis. Gastroenterology1990; 98: A578.
60.
IchidaF: Clinical experience with ursodeoxycholic acid for chronic hepatitis. Diagn Treat1961; 36: 388.
61.
NakaharaTYoshidaHBandoT: Effect of Ursosan tablets on chronic hepatic disorders. Diagn Treat1965; 50: 1070–1073.
MiyajiK: Effect of ursodeoxycholic acid on liver function of chronic liver disease. Jpn J Clin Exp Med1976; 53: 1395.
64.
YamanakaK: Study of curative effect of ursodeoxycholic acid for chronic hepatitis by double-blind trial. Diagn Treat1976; 64: 2150.
65.
LeuschnerULeuschnerMSieratzkiJ: Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years' follow-up. A pilot study. Dig Dis Sci1985; 30: 642–649.
66.
IdeoGBellatiGPedraglioE: Efficacy of ursodeoxycholic acid in lowering alanine aminotransferase and gamma-glutamyl transpeptidase serum levels in patients with chronic active hepatitis and primary biliary cirrhosis. Curr Ther Res1990; 47: 62–66.
67.
OhyaT: Long-term administration of ursodeoxycholic acid in patients with chronic hepatitis. A comparison of the effect of two doses on liver function. Jpn Pharmacol Ther1985; 13: 271–276.
68.
Del Vecchio BlancoCCaporasoNGentileS: Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: a double-blind controlled trial. J Int Med Res1982; 10: 278–282.
69.
BellentaniSTabarroniGBarchiT: Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase semm levels in patients with hypertransarninasemia. Results from a double-blind controlled trial. J Hepatol1989; 8: 7–12.
70.
MalavoltiMSamaCMorselli LabateAM: Ursodeoxychlic acid (UDCA) improves serum albumin levels in chronic active hepatitis. Gastroenterology1990; 98: A606.
71.
LirussiFOrlandoRIemmonoRM: Effect of UDCA and silymarin on liver function in patients with chronic active hepatitis with cirrhosis: a prospective study. J Hepatol1989; 9 (suppl 1): S184.
72.
PoddaMGhezziCBattezzatiPM: Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology1990; 98: 1044–1050.
73.
FrimanSPerssonHSvanvikJ: Does adjuvant ursodeoxycholic acid prevent early rejection in liver transplant recipients?Gastroenterology1990; 98: A587.
